Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

32.34 -0.96 (-2.88%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,641,137
Open 33.23
Bid (Size) 31.25 (400)
Ask (Size) 34.85 (100)
Prev. Close 33.30
Today's Range 30.92 - 33.23
52wk Range 12.91 - 36.15
Shares Outstanding 60,717,176
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025
From Travere Therapeutics, Inc.
Via Business Wire
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025.... 
Via MarketMinute
Topics Intellectual Property

Performance

YTD
+70.5%
+70.5%
1 Month
+23.4%
+23.4%
3 Month
+90.9%
+90.9%
6 Month
+61.5%
+61.5%
1 Year
+83.1%
+83.1%

More News

Read More
Travere Therapeutics to Participate at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For October 30, 2025
Via Benzinga
Top 2% Travere Looks To Top Buy Zone After Screaming Up Another Beat
Via Investor's Business Daily
Topics Earnings
Travere Therapeutics Inc (NASDAQ:TVTX) Q3 2025 Earnings Soar, Fueled by FILSPARI Sales and Milestone Payments
Via Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Travere Therapeutics Reports Third Quarter 2025 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics to Report Third Quarter 2025 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025
From Travere Therapeutics, Inc.
Via Business Wire
Novartis Strengthens Kidney Disease Pipeline With Promising Data
Via Benzinga
Travere Therapeutics Inc (NASDAQ:TVTX) Shows Strong Growth Momentum and Technical Setup
Via Chartmill
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
From Travere Therapeutics, Inc.
Via Business Wire
The Analyst Verdict: Travere Therapeutics In The Eyes Of 9 Experts
Via Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
Travere Shares Are Trading Higher Wednesday: What's Going On?
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Daktronics, Potbelly, CoreWeave, GameStop And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Why Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year High
Via Investor's Business Daily
Travere Therapeutics Stock Soars Pre-market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug Application
Via Stocktwits
Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGS
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism
From Travere Therapeutics, Inc.
Via Business Wire
FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari
Via Benzinga

Frequently Asked Questions

Is Travere Therapeutics, Inc. - Common Stock publicly traded?
Yes, Travere Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Travere Therapeutics, Inc. - Common Stock trade on?
Travere Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Travere Therapeutics, Inc. - Common Stock?
The ticker symbol for Travere Therapeutics, Inc. - Common Stock is TVTX on the Nasdaq Stock Market
What is the current price of Travere Therapeutics, Inc. - Common Stock?
The current price of Travere Therapeutics, Inc. - Common Stock is 32.34
When was Travere Therapeutics, Inc. - Common Stock last traded?
The last trade of Travere Therapeutics, Inc. - Common Stock was at 11/07/25 04:00 PM ET
What is the market capitalization of Travere Therapeutics, Inc. - Common Stock?
The market capitalization of Travere Therapeutics, Inc. - Common Stock is 1.96B
How many shares of Travere Therapeutics, Inc. - Common Stock are outstanding?
Travere Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.